Investigational drug · Phase 3
Ribupatide
Also called: KAI-9531
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Obesity With Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "Ribupatide"
First trial start
2025
Dec 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ribupatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Obesity With Diabetes
- Overweight With Diabetes
- Participants With Obesity and Knee Osteoarthritis
Approved drugs for the same conditions: Obesity and weight management · Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Ribupatide" as an intervention, largest first.
- Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07284875 · 2,530 participants · Start Dec 18, 2025 · Primary completion Feb 2028
Drug: Ribupatide; Placebo · For: Obesity; Overweight
Sites: Anniston, Alabama; Birmingham, Alabama; Cullman, Alabama · 110 sites in all
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07284979 · 1,270 participants · Start Dec 30, 2025 · Primary completion Mar 2028
Drug: Ribupatide; Semaglutide and 1 more · For: Obesity
Sites: Glendale, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 60 sites in all
- Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07284901 · 1,270 participants · Start Jan 12, 2026 · Primary completion Mar 27, 2028
Drug: Ribupatide; Placebo · For: Obesity With Diabetes; Overweight With Diabetes
Sites: Cullman, Alabama; Phoenix, Arizona; Sun City, Arizona · 174 sites in all
- A Trial of Ribupatide Injection in Participants With Obesity and Knee OsteoarthritisPivotal-lookingNot yet recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07709910 · 382 participants (planned) · Start Jul 2026 · Primary completion Nov 2028
Drug: Ribupatide Injection; Placebo · For: Participants With Obesity and Knee Osteoarthritis
Sites: Shanghai, China
- Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07458269 · 264 participants · Start Mar 4, 2026 · Primary completion May 2027
Drug: Ribupatide; Placebo · For: Obesity
Sites: Mesa, Arizona; Sun City West, Arizona; Irvine, California · 35 sites in all
- A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideRecruiting
KaileraIndustry
NCT07793929 · 32 participants (planned) · Start Sep 8, 2026 · Primary completion Feb 8, 2028
Drug: Ribupatide · For: End Stage Renal Disease; Renal Impairment; Obesity and 1 more
Sites: Orlando, Florida; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.
He K, Wei Y, Zhao H, et al. · Diabetes Obes Metab 2026
- Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.
Zhao L, Chen Y, Cheng Z, et al. · JAMA 2026
- Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: Research Summary.
· JAMA 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.